BCC
51 programs · 49 companies
Programs
51
Companies
49
Trials
47
MOAs
35
KRASG12DiALKiAnti-AβCFTRmodFGFRiKRASG12CiIL-17iJAK1/2iEZH2iMDM2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | NDA/BLA | FGFR | ||
| Zanuratamab | Phase 1/2 | CDK2 | ||
| Zenotinib | Phase 1 | CGRP | ||
| ALN-8757 | Preclinical | TIGIT | ||
| SRP-9822 | Phase 3 | SOS1 | ||
| Niralucimab | Phase 1 | ALK | ||
| Doxazasiran | Phase 1 | TIM-3 | ||
| RLA-6817 | Phase 3 | TIGIT | ||
| Peminaritide | NDA/BLA | CD20 | ||
| NMR-223 | NDA/BLA | C5 | ||
| TSH-7567 | Phase 1/2 | WRN | ||
| SDG-1247 | Phase 1 | CD19 | ||
| 450-8195 | NDA/BLA | TROP-2 | ||
| Doxafotisoran | NDA/BLA | TIM-3 | ||
| Sovanesiran | Phase 1 | CFTR | ||
| Mavunesiran | Preclinical | JAK1 | ||
| Geliglumide | Phase 1 | PI3Kα | ||
| NKT-344 | Phase 1 | C5 | ||
| COR-7645 | NDA/BLA | IL-13 | ||
| Sovafotisoran | Preclinical | KRASG12D | ||
| Tiranaritide | Preclinical | FLT3 | ||
| Sovazumab | NDA/BLA | IL-17A | ||
| BTA-3746 | Phase 2 | C5 | ||
| Miritinib | Phase 2/3 | BET | ||
| ALE-9377 | Approved | CD19 | ||
| Bemazanubrutinib | Phase 2/3 | AuroraA | ||
| Kemamavacamten | Preclinical | AHR | ||
| Surainavolisib | NDA/BLA | MALT1 | ||
| 996-4673 | Phase 1/2 | APOC3 | ||
| Nidatenlimab | Approved | AHR | ||
| Teranesiran | Phase 1 | WRN | ||
| Tiratinib | Preclinical | FLT3 | ||
| TRD-3150 | Preclinical | B7-H3 | ||
| Gozezumab | Approved | TIGIT | ||
| Nirarasimod | Phase 2/3 | PARP | ||
| Zanumavacamten | Phase 1/2 | DLL3 | ||
| CAL-4055 | Phase 3 | CD123 | ||
| MRK-6740 | Phase 2/3 | B7-H3 | ||
| NAN-2606 | Phase 1 | EZH2 | ||
| Zanurapivir | Phase 2 | CD47 | ||
| URG-1959 | Phase 3 | C5 | ||
| MYG-2072 | Phase 2 | Aβ | ||
| Riborelsin | Phase 3 | IL-23 | ||
| Doxacagene | Approved | KRASG12C | ||
| Olpasacituzumab | Approved | SOS1 | ||
| TAB-3211 | Phase 3 | APOC3 | ||
| JAM-9461 | Phase 2/3 | AuroraA | ||
| Motanesiran | Phase 2/3 | MDM2 | ||
| RIC-4332 | Phase 3 | CD123 | ||
| EGI-5078 | Phase 2 | FGFR | ||
| Gelirasimod | NDA/BLA | CD38 |
Trials (47)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07892630 | Doxarasimod | NDA/BLA | Terminated |
| NCT06433688 | ALN-8757 | Preclinical | Terminated |
| NCT05505057 | SRP-9822 | Phase 3 | Terminated |
| NCT04377739 | SRP-9822 | Phase 3 | Completed |
| NCT07548939 | SRP-9822 | Phase 3 | Completed |
| NCT05583343 | Doxazasiran | Phase 1 | Terminated |
| NCT05828103 | RLA-6817 | Phase 3 | Terminated |
| NCT04511092 | RLA-6817 | Phase 3 | Active |
| NCT04653972 | RLA-6817 | Phase 3 | Not yet recr... |
| NCT04690145 | RLA-6817 | Phase 3 | Completed |
| NCT08238537 | TSH-7567 | Phase 1/2 | Not yet recr... |
| NCT05579887 | Mavunesiran | Preclinical | Terminated |
| NCT05124177 | Geliglumide | Phase 1 | Terminated |
| NCT03685387 | COR-7645 | NDA/BLA | Completed |
| NCT06304414 | Tiranaritide | Preclinical | Not yet recr... |
| NCT06137469 | Sovazumab | NDA/BLA | Not yet recr... |
| NCT05526439 | Miritinib | Phase 2/3 | Recruiting |
| NCT06992518 | ALE-9377 | Approved | Not yet recr... |
| NCT03662120 | ALE-9377 | Approved | Recruiting |
| NCT07135675 | Bemazanubrutinib | Phase 2/3 | Active |